Synthesis and Assembly of Hepatitis B Virus-Like Particles in a *Pichia pastoris* Cell-Free System

Alex J. Spice$^{1,2}$, Rochelle Aw$^{1,2}$, Daniel G. Bracewell$^3$ and Karen M. Polizzi$^{1,2}$*

$^1$Department of Chemical Engineering, Imperial College London, London, United Kingdom, $^2$The Imperial College Centre for Synthetic Biology, Imperial College London, London, United Kingdom, $^3$Department of Biochemical Engineering, University College London, London, United Kingdom

Virus-like particles (VLPs) are supramolecular protein assemblies with the potential for unique and exciting applications in synthetic biology and medicine. Despite the attention VLPs have gained thus far, considerable limitations still persist in their production. Poorly scalable manufacturing technologies and inconsistent product architectures continue to restrict the full potential of VLPs. Cell-free protein synthesis (CFPS) offers an alternative approach to VLP production and has already proven to be successful, albeit using extracts from a limited number of organisms. Using a recently developed *Pichia pastoris*-based CFPS system, we have demonstrated the production of the model Hepatitis B core antigen VLP as a proof-of-concept. The VLPs produced in the CFPS system were found to have comparable characteristics to those previously produced *in vivo* and *in vitro*. Additionally, we have developed a facile and rapid synthesis, assembly and purification methodology that could be applied as a rapid prototyping platform for vaccine development or synthetic biology applications. Overall the CFPS methodology allows far greater throughput, which will expedite the screening of optimal assembly conditions for more robust and stable VLPs. This approach could therefore support the characterization of larger sample sets to improve vaccine development efficiency.

**Keywords:** cell-free protein synthesis, virus-like particles, *Pichia pastoris*, synthetic biology, hepatitis B core antigen

**INTRODUCTION**

Cell-free protein synthesis was developed as early as the 1960s, where it was critical in determining the genetic code (Nirenberg and Matthaei, 1961). Over the decades, advances in synthetic biology are driving a renaissance in CFPS and it is emerging as a transformative platform technology (Carlson et al., 2012). This pique in interest is mainly due to the capacity to produce protein in a rapid and facile manner, providing benefits to multifarious applications. These include the design of *de novo* metabolic pathways (Hodgman and Jewett, 2012), personalized medicine (Ogonah et al., 2017) and biosensing (Pardee et al., 2016). CFPS has also shown distinct advantages in producing difficult-to-express proteins, such as those toxic to the cell *in vivo* (Katzen et al., 2005). Finally, due
to the unparalleled access to the reaction environment, optimization and characterization can be achieved with an ease that far exceeds in vivo systems, creating opportunities for high throughput screening and rapid prototyping.

Cell-free extracts based on a variety of host organisms are continually being developed. Arguably, extracts could be prepared from any cultivatable cell-type. The most commonly utilized systems and those which are commercially available are from Escherichia coli (Chen and Zubay, 1983), Chinese hamster ovary cells (CHO) (Brödel et al., 2014), wheat-germ extract (WGE) (Anderson et al., 1983; Madin et al., 2000), rabbit reticulocyte lysate (RRL) (Jackson and Hunt, 1983) and insect (SF9) cells (Stech et al., 2014). Developing new extracts is still of great interest, unlocking access to advantageous properties of the organisms from which they are derived. The available repertoire of developed CFPS extracts is still expanding and now includes HEK293 (Bradrick et al., 2013) Saccharomyces cerevisiae (Gan and Jewett, 2014), BY-2 tobacco cells (Buntru et al., 2014), Streptomyces venezuelae (Moore et al., 2017), Bacillus megaterium (Moore et al., 2018), Vibrio natriegens (Gan and Jewett, 2014) and most recently Pichia pastoris (Aw and Polizzi, 2019).

Pichia pastoris (syn. Komagataella spp.) has developed over the past three decades to become the most commonly utilized protein expression system after E. coli, for both lab and industrial-scale protein production (Bill, 2014). The popularity of P. pastoris largely stems from high volumetric productivity, afforded by the ability of the organism to grow to high cell densities (Darby et al., 2012). In addition, P. pastoris has proven to be highly versatile, with thousands of proteins successfully synthesized to date (Ahmad et al., 2014). It has also become an important expression host for the production of VLP vaccines (Wang et al., 2016).

Virus-like particles are supramolecular protein assemblies, composed of capsid-forming proteins that self-assemble, mimicking the structure of the native viruses from which they are derived (Huang et al., 2017). VLPs are non-infectious and unable to replicate, as they lack a viral genome, removing the concerns about infectivity often associated with live-attenuated or inactivated viruses. This makes VLPs exciting potential vaccine candidates, as they also display strong immunogenicity and the induction of innate and adaptive immunity in animals and humans (Roldão et al., 2010; Crisci et al., 2012). The first VLP vaccine was commercialized in 1986 and was comprised of the hepatitis B virus surface antigen, demonstrating the efficiency and potential of VLP vaccines (Gerety, 1984). In recent years there has been a shift toward engineering increased complexity, with third generation VLPs finding applications in imaging (Manchester and Singh, 2006; Schwarz and Douglas, 2015), catalysis (Patterson et al., 2014, 2015; Maity et al., 2015) and template synthesis (Wnêk et al., 2013). Additionally, VLPs are ideal for the development of platforms for heterologous antigen display, drug encapsulation and chimeric and/or hybrid VLP vaccines (Hill et al., 2017). Advances in synthetic biology are aiding these efforts by widening the repertoire of potential antigens and improving the modularity of these platforms. Despite the attractive attributes, the use of VLPs as vaccines is still hampered by issues related to their production, such as particle integrity, yield, and purification, leading to a demand for new manufacturing approaches to address these challenges (Charlton Hume et al., 2019).

Due to the ability to quickly synthesize protein, CFPS could enable portable and expeditious manufacture of vaccines in response to emerging pathogenic threats or in resource-limited areas. Cell-free systems capable of VLP production may also find use as rapid prototyping platforms for potential VLP vaccine candidates prior to full-scale industrial manufacture or wider nanotechnology applications. Of particular interest is identifying the optimal VLP assembly conditions, which are easier to establish in vitro due to the open nature of the reaction environment. Greater understanding of VLP assembly may help overcome issues related to architectural heterogeneity commonly associated with inconsistent product generation. Additionally, in vivo expression of VLPs can cause cellular toxicity that inhibits growth, such as in the case of the toxic intermediate A2 protein, which was successfully produced and incorporated into Q8 VLPs in a cell-free system (Smith et al., 2012).

A number of CFPS systems have been utilized for the production of VLPs. Hepatitis B virus core antigen VLP has been produced in extracts derived from E. coli (Bundy et al., 2008) and RRL (Ludgate et al., 2016). Human papillomavirus L1 VLP has been produced in S. cerevisiae cell-free systems (Wang et al., 2008) and Human norovirus VLP has been produced in E. coli cell-free systems (Sheng et al., 2017). WGE has been used extensively for the production of VLPs derived from Hepatitis B virus (Lingappa, 1994), Hepatitis C virus (Klein et al., 2004), Human immunodeficiency virus (HIV) (Lingappa et al., 1997), and Simian immunodeficiency virus (SIV) (Doolher and Lingappa, 2004; Lingappa et al., 2005).

The history of P. pastoris as a robust and versatile expression host able to produce VLPs from diverse origins suggests the recently developed CFPS system could be ideally suited as a high-throughput VLP manufacturing and characterization platform. The platform could be specifically suitable for the rapid optimization and validation of DNA constructs and protein variants in vitro, circumventing some of the lengthy cloning procedures associated with strain development, prior to full-scale industrial manufacture in vivo. Additionally, recombinant protein production in the P. pastoris CFPS system is relatively untested. Probing the capabilities of the P. pastoris CFPS system for complex recombinant protein production is therefore a valuable measure of the future potential of the platform for synthesis of more complex biopharmaceuticals.

As a first step toward this goal, the wild-type Hepatitis B virus core antigen (HBc) VLP was selected as a proof-of-concept, as it is one of the best characterized model VLPs. Even though there are no clinically approved native non-chimeric HBc VLP vaccines, HBc VLPs are a popular scaffold molecule for the construction of prophylactic and therapeutic vaccine candidates, many of which are currently undergoing clinical trials (Kutsch et al., 2012). HBc VLPs are an excellent platform for foreign antigen presentation due to their high amenability to foreign insertions, and efficient self-assembly (Pumpens and Grens, 2002) and therefore have been developed for the display of foreign antigens from a vast array of pathogens (Charlton Hume et al., 2019). Some of the chimeric and/or hybrid VLPs have been approved
for clinical or veterinary use; for example, against influenza (De Filette et al., 2008; Fiers et al., 2009; Kazaks et al., 2017) and malaria (Schödel et al., 1994; Sällberg et al., 2002; Nardin et al., 2004). Unlike the HBs-Ag which is an enveloped VLP, the HBC VLP is non-enveloped and therefore structurally less complex. This relative simplicity makes it a good test case for production in a cell-free system. In this study we have developed a rapid method for the production and partial purification of HBC VLPs produced in a *P. pastoris* cell-free system.

**MATERIALS AND METHODS**

**Media and Growth Conditions**

Bacterial strains were cultured in Miller lysogeny broth (LB) medium (1% peptone from casein, 0.5% yeast extract, 1% NaCl) supplemented with 37 µg ml⁻¹ Kanamycin (Sigma–Aldrich, Dorset, United Kingdom). *P. pastoris* strains were cultured in a rich yeast peptone dextrose (YPD) medium (2% peptone from casein, 1% yeast extract, and 2% dextrose) and with 350 µg ml⁻¹ Geneticin (VWR, Lutterworth, United Kingdom) for selection. *P. pastoris* strains were cultured in baffled glass flasks or in 50 ml Falcon tubes at a volume of no more than 20% of the total volume of the vessel starting from an OD₆₀₀ of 0.1.

**Strains**

Bacterial recombinant DNA manipulation was carried out in *E. coli* strain NEB 5–α (New England Biolabs (NEB), Hertfordshire, United Kingdom). *P. pastoris* (syn. *Komagataella phaffii*) strain FHL1 was described previously (Aw and Polizzi, 2019).

**Plasmid Construction**

The CFPS expression plasmid was generated using the Gibson DNA assembly method as described previously (Gibson et al., 2009). The pET−28b vector (Merck UK Ltd., Hertfordshire, United Kingdom) was used as a backbone. The full-length wild-type (WT) HBC core antigen (adw serotype) codon-optimized for *P. pastoris* and the cricket paralysis virus (CrPV) internal ribosome entry site (IRES) sequences were synthesized by GeneArt™ (Thermo Fisher Scientific, Paisley, United Kingdom). In order to make the expression constructs, desired fragments were amplified with 30 bp of homology using primers purchased from Thermo Fisher Scientific using Phusion® High Fidelity DNA polymerase (New England Biolabs). A Kozak sequence (GAAACG) was included in the primers, directly upstream of the coding region. This sequence was selected based on previously displayed efficacy in the production of recombinant proteins in *P. pastoris* and is recommended in the ThermoFisher PichiaPink™ Expression System manual. The PCR reaction products were gel extracted using the Zymoclean™ Gel DNA Recovery kit (Zymo Research Corporation, Irvine, CA, United States) prior to the assembly reaction. After confirmation of the correct plasmid assembly, a synthetic 50 bp polyA tail was generated using annealed primers and inserted into the vector by restriction cloning using XhoI and NotI (NEB). The plasmid material generated for CFPS reactions was extracted using the Qiagen Maxi Prep Kit (Qiagen, Crawley, United Kingdom).

**Crude Extract Preparation and Coupled Cell-Free Protein Synthesis**

*Pichia pastoris* cells were grown and extracts were prepared as previously described (Aw and Polizzi, 2019). Briefly, overnight cultures of *P. pastoris* strain FHL1 were grown in 5 ml of YPD medium and then used to inoculate 200 ml of YPD medium to an OD₆₀₀ of 0.1. Cell growth was allowed to proceed to an OD₆₀₀ of 18–20 at 30°C, 250 rpm. Cells were harvested, washed, homogenized and prepared using the previously described methodology (Aw and Polizzi, 2019). Cell-free protein synthesis reactions were performed by a coupled *in vitro* transcription/translation system at a volume of 50 µL at room temperature for 3 h with no shaking as previously detailed (Aw and Polizzi, 2019).

**In vitro Capsid Assembly and Purification**

The protocol for capsid assembly and the assembly reaction mixture was adapted from Ludgate et al., 2016. The assembly reaction mixture contained 3 µL of the product of the coupled CFPS reaction per 10 µL total assembly reaction volume and consisted of 1x restriction buffer 3 (100 mM NaCl, 50 mM Tris–HCl, 10 mM MgCl₂, 1 mM dithiothreitol (DTT), pH 7.9; (NEB) supplemented with 1x complete™ mini, EDTA-free protease inhibitor cocktail (Roche, Basel, Switzerland) and 1 U µL⁻¹ Murine RNase inhibitor (NEB). For reactions supplemented with exogenous phosphatase, 1 U µL⁻¹ of calf intestinal alkaline phosphatase (CIP; NEB) was supplemented into the assembly reaction mixture. The reaction mixtures were incubated overnight (16 h) at 37°C. At this stage, samples were then either concentrated or the purification process continued. For concentration, Vivaspin® 500, 100 kDa MWCO centrifugal concentrators (Sartorius, Göttingen, Germany) were used according to the manufacturer’s instructions and samples were buffer exchanged three times with PBS to a final volume of 50 µL.

For purification, after overnight assembly, the reaction mixture was heated at 60°C for 1 h to precipitate contaminating proteins followed by centrifugation (5000 × g, 10 min). After centrifugation, the supernatant was collected, and solid ammonium sulfate added to 40% saturation. The mixture was incubated on a laboratory rotator for a minimum of 2 h or overnight at 4°C. The mixture was centrifuged (10,000 × g, 30 min) and the resulting protein pellet resuspended in a minimal volume of phosphate-buffered saline (PBS).

**SDS-PAGE Gel Analysis**

Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS–PAGE) was performed using 15% Tris–HCl SDS-PAGE gels. Protein samples were denatured by boiling for 15 min in reducing SDS sample buffer (0.0625 M Tris–HCl, pH 6.8, 2.3% (w/v) SDS, 10% (w/v) glycerol, 0.01% Bromophenol blue, 5% (v/v) β-mercaptoethanol). Molecular weight was estimated by using a pre-stained protein ladder (Pageruler,
10–170 kDa, Thermo Fisher Scientific). SDS-PAGE gels were stained using SimplyBlue™ SafeStain (Invitrogen, Carlsbad, CA, United States) according to the manufacturer’s instructions.

**Dynamic Light Scattering (DLS) Measurements**

Dynamic light scattering measurements were performed using a Malvern Zetasizer Nano ZS instrument (Malvern Instruments Ltd., Worcestershire, United Kingdom). The software utilized to collect and analyze the data was Zetasizer Series 7.13 from Malvern. Forty μL of each sample was analyzed in a 45 μL low-volume glass cuvette. All measurements were conducted at a controlled temperature of 25°C and for each sample 15 runs of 70 s were performed with three repetitions.

**Transmission Electron Microscopy (TEM) Analysis**

A 3.4 μL sample of purified VLP solution between 0.02–0.05 mg mL⁻¹ was applied to a carbon coated copper/Formvar grid and negatively stained with 2% w/v uranyl acetate, pH 4. Images were taken by a TEMCAM XF416 (TVIPS, Oslo, Norway) camera in a CM200 (Philips, Amsterdam, Netherlands) electron microscope at an acceleration voltage of 200 kV. ImageJ software (version 1.51) (Maryland, United States) was used to process the TEM images and add scale bars.

**RESULTS AND DISCUSSION**

**Synthesis, Assembly and Crude Purification of Hepatitis B Viral Capsids**

The full-length wild-type HBc VLP was selected as a proof-of-concept due to extensive previous characterization and its use as a chassis molecule for novel vaccine designs (Pumpens and Grens, 2001). The icosahedral HBc VLP is composed of multiple copies of a single 21 kDa protein, the HBc protein. The WT HBc monomer can be divided into three distinct regions: an NTD (position 1–140) responsible for capsid assembly, a CTD (positions 149–183 or 185, depending on the strain) responsible for nucleic acid binding, and a linker region (position 140–149). The assembly domain contains the major immunodominant region, comprised of two α-helices forming the spikes on the particles. The full-length HBc forms dimers and the capsid itself is dimorphic, assembling into both the $T = 3$ (90 dimers) and $T = 4$ (120 dimers) icosahedral VLPs with diameters of 32 nm and 35 nm, respectively (Crowther, 1994; Roseman et al., 2012). In recent years, HBc VLPs have been used as a versatile chassis for both nanotechnology and vaccine applications (Chackerian, 2007; Ludwig and Wagner, 2007) primarily due to particle stability and integrity.

The full-length HBc gene (amino acids 1–183, codon-optimized for *P. pastoris*) was cloned into the pET–28b vector (Merck United Kingdom Ltd.) using the Gibson Assembly method (Gibson et al., 2009). *Pichia pastoris* CFPS reactions were performed to synthesize the HBc in a reaction volume of 50 μL at room temperature without shaking the cultures for 3 h.

During our early experiments, we found that the HBc VLPs were unable to self-assemble directly in the CFPS reaction (data not shown). Previous studies have shown that HBc VLP self-assembly *in vitro* is well known to be highly dependent on monomer concentration (Lingappa et al., 2005; Ludgate et al., 2016). When the concentration of HBc dimer exceeds a critical concentration, nearly all free dimer associates into capsid (Katen and Zlotnick, 2009). The HBc concentration required for assembly *in vitro* is high (40–80 μM) at physiological salt concentrations (Wingfield et al., 1995; Tan et al., 2013), although spontaneous self-assembly of the HBc VLP has also been shown to be triggered by increasing the salt concentration (Bundy et al., 2008). Based on the previously reported yield of luciferase produced in our system (~4.5 μM) (Aw and Polizzi, 2019), we postulated that lack of assembly was due to low dimer concentration prohibiting capsid self-assembly. In a report describing HBc VLP production in an RRL-based CFPS system, it was shown that full-length HBc VLP assembly can be achieved at lower dimer concentrations by modulating the phosphorylation state of the CTD (Ludgate et al., 2016). We therefore aimed to recreate the capsid assembly conditions from this study to ascertain whether the HBc synthesized in our system could be induced to self-assemble into capsids, even at concentrations below the self-assembly threshold. To achieve this, we designed a synthesis, assembly and purification protocol for determining the optimum particle assembly conditions (Figure 1).

In order to provide adequate time for capsid assembly, the completed CFPS reactions containing HBc were diluted into the assembly reaction mixture and incubated overnight at 37°C for 16 h. Exogenous CIP, as a broad spectrum phosphatase that can also act on protein, was supplemented into selected samples to dephosphorylate the CTD of the HBc in order to modulate capsid assembly (Ludgate et al., 2016). Since the CTD undergoes non-specific RNA binding, which is modulated by its phosphorylation state, inclusion of an RNase inhibitor in the assembly reaction mixture was also essential to preserve RNA integrity (Ludgate et al., 2016). It is highly probable therefore that dephosphorylation of the CTD promotes non-specific interactions with nucleic acids, facilitating capsid assembly. It has been previously shown that a positively charged CTD interacts with negatively charged nucleic acids to enable capsid assembly at 5 nM (Klein et al., 2004) and the removal of the phosphate may contribute to increasing the local positive charge.

After incubation, centrifugation was conducted to remove aggregates and the supernatant was applied to a 100 kDa MWCO centrifugal concentrator and buffered-exchanged three times against PBS. A high MWCO membrane is frequently used in HBc VLP production as a concentration and rudimentary purification step (Kazaks et al., 2017; Wetzel et al., 2018).

Samples were taken from the retentate of the concentrator and the resultant flow-through for SDS-PAGE analysis (Figure 2). The HBc monomer has a molecular weight of 21 kDa, but no band of this size was observed across all samples. A band was, however, observed at approximately 40 kDa for the CIP-treated samples (green arrow) which could be indicative of the HBc dimer (42 kDa). Presence of a band at the expected size of the dimer in the CIP-treated samples suggested HBc VLP...
Spice et al. Cell-Free Production of VLPs

FIGURE 1 | Work-flow schematic of HBc VLP synthesis, assembly and centrifugal concentrator purification. Created with biorender.com.

characterization by DLS
To validate HBc VLP assembly, retentate samples taken after centrifugal concentration were subjected to morphological analysis. Samples of 40 μL were obtained from the concentration step and transferred to a 45 μL low-volume glass cuvette. Using DLS, the diffusion of the particles moving under Brownian motion was measured and the particles sizes of VLPs calculated. Both the CIP-treated and untreated HBc samples gave a positive result from the DLS characterization (Figure 3). The untreated HBc sample (Figure 3A) displayed a Z-average particle size of 36.89 nm. Considering our initial hypothesis that VLPs would be unable to assemble as a result of low dimer concentration, this was an unexpected result. It is possible that the concentration of monomer produced in our CFPS system is sufficient for capsid self-assembly, but only when subjected to the conditions provided by the assembly buffer. The beneficial conditions promoting capsid assembly could be the increased salt concentration of the assembly buffer, which was previously shown to trigger capsid self-assembly (Bundy et al., 2008), the inclusion of RNase inhibitor, which preserves RNA integrity thereby facilitating co-localization of free dimer, or a combination of the two. The CIP-treated HBc sample (Figure 3B) displayed a Z-average particle size of 37.97 nm. Both observed Z-average particle sizes are close to the reported size of the T = 4 HBc VLP (∼35 nm) (Crowther, 1994; Zlotnick et al., 1996). The T = 4 capsid has been reported as the most abundant product of WT HBc produced by in vitro self-assembly (∼95%) (Zlotnick et al., 1999).

characterization by TEM
In order to verify that the products of our rapid synthesis, assembly and purification protocol contained correctly formed assembly, though further confirmation was required. It is highly likely that the HBc monomer is not visible in the flowthrough of the untreated HBc samples due to dilution. Based on previous concentrations of luciferase produced and the molecular weight of HBc, the concentration is insufficient to meet the criteria for SDS-PAGE detection with SimplyBlue™ SafeStain (Invitrogen). It is worth noting that the other prominent band found in the CIP-treated samples at approximately 70 kDa is the CIP monomer (red arrow), which is added at very high concentrations.
FIGURE 3 | Dynamic light scattering measurements to characterize particle size distribution of the assembled HBc VLPs. (A) HBc VLPs obtained from incubation in assembly buffer in the absence of CIP (untreated assembly) (B) HBc VLPs obtained from incubation in assembly buffer supplemented with CIP (CIP-treated assembly). Samples are displayed as intensity percentage with three technical replicates.

FIGURE 4 | Characterization of HBc VLPs obtained from assembly and crude purification using transmission electron microscopy (TEM). (A) HBc VLPs obtained from incubation in assembly buffer in the absence of CIP (untreated assembly) (B) HBc VLPs obtained from incubation in assembly buffer supplemented with CIP (CIP-treated assembly). Scale-bar size: 100 nm.

HBc VLPs, TEM with 2% uranyl acetate negative staining was used (Figure 4). The average diameter for the untreated HBc VLPs was 29.3 nm (SD = 1.4 nm, n = 13) and from the CIP-treated HBc VLPs the average diameter was 28.9 nm (SD = 1.8 nm, n = 19). The average size of particles from both samples correlate with previously reported diameters of 30.7 nm from HBc VLPs produced using in vitro methods (Bundy et al., 2008) and 30 nm from in vivo methods (Zlotnick et al., 1996). Interestingly, a greater number of fully assembled particles were visible in the CIP-treated sample relative to the untreated sample. This could explain why a faint band with a size corresponding to the dimer was visible in the SDS-PAGE analysis for the CIP-treated sample (Figure 2, Lane 2), but no band corresponding to the expected size of the monomer or dimer was observed for the untreated samples (HBc) (Figure 2, Lane 1). As previously discussed, dephosphorylation of the CTD likely boosts capsid assembly by promoting non-specific interactions with nucleic acids, facilitating capsid self-assembly. Despite this, there was no great observable difference in average particle size or morphology with both samples still displaying a proportion of partially assembled or disassembled particles, in addition to other smaller protein contaminants. It is possible the smaller contaminants are HBc monomer, CIP or host-cell protein carried through the purification. The presence of host-cell contaminants correlates with the SDS-PAGE analysis (Figure 2) suggesting further development of the purification protocol was needed.

Heat-Treatment and Ammonium Sulfate Purification of Assembled HBc VLPs

Once the successful synthesis and assembly of HBc VLPs was demonstrated, the next aim was to develop an improved methodology for VLP purification (Figure 5). We decided to develop this process using the CIP-treated samples, as the TEM characterization indicated an increased average number of
particles relative to the untreated samples. In order to keep in
line with creating a simple and rapid purification process, we
strived to avoid more time-consuming purification steps, such
as chromatography, and those that are costly and poorly scalable
for production purposes, such as ultracentrifugation. It has been
reported that an efficient method of removing host-cell protein
contaminants is the inclusion of a heat treatment step which is
both fast and simple (Ng et al., 2006; Lee et al., 2015; Li et al.,
2018). As fully-assembled HBC VLP has been shown to be highly
thermostable (Ng et al., 2006; Lee and Tan, 2008), heat-labile host-
cell proteins can be denatured and precipitated from solution.
Toward this end, we removed the centrifugal concentrator
step and included a 1 h incubation at 60°C after the initial
assembly reaction in order to remove protein contaminants and
improperly assembled HBC VLPs. After heating, the reaction
mixture was subjected to centrifugation and the supernatant
collected for ammonium sulfate precipitation.

Ammonium sulfate precipitation is a well-established method
for separation of HBC VLPs and is widely used as a preparatory
purification step (Palenzuela et al., 2002). Particles were
precipitated by addition of solid ammonium sulfate to 40%
saturation (Yang, 2005) followed by incubation at 4°C on a
rotator for a minimum of 2 h. The reaction was then centrifuged,
and the resultant precipitate resuspended in a minimal volume
of PBS, thereby purifying and concentrating the HBC VLPs.

To validate the efficacy of our new purification method,
samples were taken from the precipitate and supernatant from
each step in the purification process for SDS-PAGE analysis (Figure 6).

The initial heat treatment step, included to denature and precipitate less thermostable host-cell proteins, appears to
remove a large number of contaminants as shown in Lanes 5
and 6 which correspond to the resuspended precipitates from the
heat treatment of the HBC assembly reaction containing CIP and
negative control. Heat treatment alone does result in sufficient
purification to detect the presence of a band at approximately
20 kDa in the supernatant of the HBC assembly reaction (Lane
7), which correlates to the expected size of the HBC monomer
(21 kDa). There are still a number of other protein contaminants
present, including a band at 70 kDa indicative of CIP. CIP
cannot be heat inactivated for removal unless heated to 80°C,
which would cause dissociation of the assembled HBC VLPs
(Li et al., 2018). Despite the presence of CIP, we note that much
of the CIP is removed during the improved purification process.
For example, in Figure 7 the CIP band in lane 7 (representing CIP
remaining in the sample after heat treatment alone) is much more
intense relative to that of the HBC monomer than the CIP band in
lane 3 (representing CIP remaining after both heat treatment and
ammonium sulfate precipitation) relative to the HBC monomer.

To improve the purity of the VLPs, a number of possible
strategies could be employed. The concentration of CIP used
in this study was selected based on that previously reported
(Ludgate et al., 2016); however, a lower concentration may still
Figure 6

much greater total protein concentration compared to those in the HBc dimer in Figure 2. The presence of a single band indicative of the HBc monomer between sample preparation and loading. It has previously been reported that disulfide re-oxidation can occur during SDS-PAGE (Kumar et al., 1993; Grigorian, 2005) and both the HBc monomer and dimer have been previously observed to co-occur (Storni and Bachmann, 2004).

The total protein concentration of the purified HBc VLP sample was obtained by measuring protein absorbance at 280 nm (A280) and found to be 68 µg ml⁻¹. Densitometry analysis conducted using the ImageJ software was used to estimate the yield of HBc VLP in our system at 6.4 µg ml⁻¹. This is a slight improvement on the reported yield of HBc VLP of 4 µg ml⁻¹ previously produced in a WGE system (Lingappa et al., 2005). The yield is currently considerably lower in our system compared to production of HBc VLP in vivo, with reported yields of assembled HBc VLP in *P. pastoris* up to 3 mg per 1 g wet cell weight (Freivalds et al., 2011).

Characterization of Purified HBc VLPs by TEM

We next sought to determine whether the product of our improved purification protocol contained correctly formed HBc VLP. To achieve this, TEM with 2% uranyl acetate negative staining was performed (Figure 7A). A number of fully formed HBc VLPs can be observed with an overall increase in the uniformity of their morphology compared to Figure 4. This indicates removal of partially assembled or disassembled HBc VLPs in the developed purification scheme relative to the initial TEM analysis using the crude purification method (Figure 4). A number of misfolded or aggregated proteins still persist in the sample, however. Based on the SDS-PAGE analysis in Figure 6, we postulate that these are likely to be aggregates of CIP, as only fully formed VLPs remain in the supernatant after heat treatment (Ng et al., 2006). An additional TEM grid was prepared at a lower sample concentration of 5 µg ml⁻¹. Staining was followed by three washes in filtered distilled water for 1 min each in order to attain single particle imaging for accurate size estimation (Figure 7B). The wash steps were included in the staining procedure to remove excess uranyl acetate stain and led to a reduction in stain permeation of the HBc VLPs (Figure 7B). The observed diameter for the displayed particle was approximately 29.5 nm. The reported size correlates with previously reported diameters from HBc VLP produced using *in vitro* methods (Bundy et al., 2008), *in vivo* methods (Zlotnick et al., 1996) and our previously shown assembled particle diameter of 29.4 nm using the crude purification method.

CONCLUSION

Cell-free protein synthesis is an incredibly powerful and versatile tool in synthetic biology, which can be applied in myriad ways. We have generated a rapid HBc VLP synthesis, assembly and purification scheme demonstrating the potential of the *P. pastoris* CFPS system for the production of complex supramolecular assemblies. This approach could enable ultra-scale-down rapid prototyping of protein variants for novel vaccine technologies.
Additionally, by exploiting the open nature of the reaction environment, the conditions for assembly can be optimized, alleviating the current challenges of structural heterogeneity in VLP manufacture. We plan to expand on this work, further testing the capabilities of the system by producing VLPs of increased complexity. In future, we envision increased effectiveness in response to emerging pathogenic threats, through high-throughput vaccine development approaches.

DATA AVAILABILITY STATEMENT
All datasets generated for this study are included in the article/supplementary files.

AUTHOR CONTRIBUTIONS
AS designed and performed the experiments. RA and KP helped to design the experiments. KP and DB helped to conceive the study. All authors helped to draft the manuscript and read and approved the final manuscript.

REFERENCES
Ahmad, M., Hirz, M., Pichler, H., and Schwab, H. (2014). Protein expression in Pichia pastoris: recent achievements and perspectives for heterologous protein production. *Appl Microbiol. Biotechnol.* 98, 5301–5317. doi: 10.1007/s00253-014-5732-5
Anderson, C. W., Straus, J. W., and Dudock, B. S. (1983). Preparation of a cell-free protein-synthesizing system from wheat germ. *Methods Enzymol.* 101, 635–644. doi: 10.1016/0076-6879(83)01044-7
Aw, R., and Polizzi, K. M. (2013). Biosensor-assisted engineering of a high-yield Pichia pastoris cell-free protein synthesis platform. *Biotechnol. Bioeng.* 116, 656–666. doi: 10.1002/bit.26901
Bill, R. M. (2014). Playing catch-up with *Escherichia coli*: using yeast to increase success rates in recombinant protein production experiments. *Front. Microbiol.* 5:85. doi: 10.3389/fmicb.2014.00085
Bradrick, S. S., Nagyal, S., and Novatt, H. (2013). A miRNA-responsive cell-free translation system facilitates isolation of hepatitis C virus mRNA complexes. *RNA* 19, 1159–1169. doi: 10.1261/rna.038810.113
Brödel, A. K., Sonnabend, A., and Kubick, S. (2014). Cell-free protein expression based on extracts from CHO cells. *Biotechnol. Bioeng.* 111, 25–36. doi: 10.1002/bit.25013
Bundy, B. C., Franciszkoiwicz, M. J., and Swartz, J. R. (2008). *Escherichia coli*-based cell-free synthesis of virus-like particles. *Biotechnol. Bioeng.* 100, 28–37. doi: 10.1002/bit.21716
Buntru, M., Simon, V., Holger, S., and Stefan, S. (2014). Tobacco BY-2 cell-free lysate: an alternative and highly-productive plant-based in vitro translation system. *BMC Biotechnol.* 14:37. doi: 10.1186/1427-6150-14-37
Carlson, E. D., Gan, R., Hodgman, C. E., and Jewett, M. C. (2012). Cell-free protein synthesis: applications come of age. *Biotechnol. Adv. Elsevier Inc.* 30, 1185–1194. doi: 10.1016/j.biotechadv.2011.09.016
Chackerian, B. (2007). Virus-like particles: flexible platforms for vaccine development. *Exp. Rev. Vaccines* 6, 381–390. doi: 10.1515/156805806.6.3.381
Charlton Hume, H. K., Vidigal, J., Carrondo, M. I. T., Middelberg, A. P. J., Roldão, A., and Lua, L. H. L. (2019). Synthetic biology for bioengineering virus-like particle vaccines. *Biotechnol. Bioeng.* 116, 919–935. doi: 10.1002/bit.26890
Chen, H. Z., and Zubay, G. (1983). Prokaryotic coupled transcription — translation. *Methods in Enzymol.* 101, 674–690. doi: 10.1016/0076-6879(83)01047-2
Crawley, S. W., Gharraei, M. S., Ye, Q., Yang, Y., Ravel, R., London, N., et al. (2011). Autophosphorylation activates dictyostelium myosin II Heavy Chain Kinase A by Providing a Ligand for an allosteric binding site in the a-kinase domain. *J. Biol. Chem.* 286, 2607–2616. doi: 10.1074/jbc.M110.177014
Crisci, E., Bárcena, J., and Montoya, M. (2012). Virus-like particles: the new frontier of vaccines for animal viral infections. *Vet. Immunol. Immunopathol.* 15, 211–225. doi: 10.1016/j.vetimm.2012.04.026
Crowther, R. (1994). Three-dimensional structure of hepatitis B virus core particles determined by electron cryomicroscopy. *Cell* 77, 943–950. doi: 10.1016/0092-8674(94)90142-2
Darby, R. A. J., Cartwright, S. P., Dílworth, M. V., and Bill, R. M. (2012). Which yeast species shall I choose? *Saccharomyces cerevisiae Versus Pichia pastoris* (Review). *Methods Mol. Biol.* 866, 11–23. doi: 10.1007/978-1-61779-770-5_2
De Filette, M., Martens, W., Smet, A., Schotsaert, M., Birkett, A., Londoño-Arcila, P., et al. (2008). Universal influenza A M2e-HBc vaccine protects against disease even in the presence of pre-existing anti-HBc antibodies. *Vaccine* 26, 6503–6507. doi: 10.1016/j.vaccine.2008.09.038
Dooloh, J. E., and Lingappa, J. R. (2004). Conservation of a stepwise, energy-sensitive pathway involving hp68 for assembly of primate lentivirus capsids in cells. *J. Virol.* 78, 1645–1656. doi: 10.1128/jvi.78.4.1645-1656.2004
Fiers, W., De Filette, M., El Bakkouri, K., Schepens, B., Roose, K., Schotsaert, M., et al. (2009). M2e-based universal influenza A vaccine. *Vaccine* 27, 6280–6283. doi: 10.1016/j.vaccine.2009.07.007
Freiwalds, J., Dislers, A., Ose, V., Pumphens, P., Tars, K., and Kazaks, A. (2011). Highly efficient production of phosphorylated hepatitis B core particles in yeast Pichia pastoris. *Protein Exp. Purif.* 75, 218–224. doi: 10.1016/j.pep.2010.09.010
Gan, R., and Jewett, M. C. (2014). A combined cell-free transcription-translation system from Saccharomyces cerevisiae for rapid and robust protein synthesis. *Biotechnol. J.* 9, 641–651. doi: 10.1002/biot.201300545
Gerety, R. J. (1984). “Newly licensed hepatitis B vaccine,” in *Hepatitis B, eds I. Millman, T. K. Eisenstein, and B. S. Blumberg, (Boston, MA: Springer).*
Gibson, D. G., Lai, Y., Ray-Yuan, C., Craig Venter, J., Clyde, H. A., and Hamilton, O. S. (2009). Enzymatic assembly of DNA molecules up to several hundred kilobases. *Nat. Methods* 6, 343–345. doi: 10.1038/nmeth.1318
Grigorian, A. L. (2005). Extraordinarily stable disulfide-linked homodimer of human growth hormone. *Protein Sci.* 14, 902–913. doi: 10.1101/ps.04148805
Hill, B. D., Zák, A., Khera, E., and Wen, F. (2017). Engineering virus-like particles for antigen and drug delivery. *Curr. Protein Peptide Sci.* 19, 112–127. doi: 10.2174/13892053186661122113041
Hodgman, C. E., and Jewett, M. C. (2012). Cell-free synthetic biology: thinking outside the cell. *Metab. Eng.* 14, 261–269. doi: 10.1016/j.ymben.2011.09.002

ACKNOWLEDGMENTS
The authors would like to thank Mr. Ciaran McKeown and Mr. Paul Simpson for assistance with DLS and TEM, respectively.

FUNDING
This project was funded in part with UK aid from the UK government, and the UK Department of Health and Social Care is gratefully acknowledged for funding the Future Vaccine Manufacturing Research Hub through the Engineering and Physical Sciences Research Council (EPSRC, grant number: EP/R013764/1). AS would also like to thank the EPSRC Centre for Innovative Manufacturing in Emergent Macromolecular Therapies (EP/I033270/1) for Ph.D. studentship funding.
Huang, X., Xin, W., Jun, Z., Ningshao, X., and Qinjian, Z. (2017). *Escherichia coli*-derived virus-like particles in vaccine development. *Npj Vaccines* 2:3. doi: 10.1038/s41541-017-0006-8

Jackson, R. J., and Hunt, T. (1983). Preparation and use of nuclease-treated rabbit reticulocyte lysates for the translation of eukaryotic messenger RNA. *Methods Enzymol.* 96, 50–74. doi: 10.1016/0076-6879(83)90068-1

Katen, S., and Zlotnick, A. (2009). The thermodynamics of virus capsid assembly. *Methods Enzymol.* 455, 395–417. doi: 10.1016/S0076-6879(08)04214-6

Katzen, F., Chang, G., and Kudlicki, W. (2005). The past, present and future of cell-free protein synthesis. *Trends Biotechnol.* 23, 150–156. doi: 10.1016/j.tibtech.2005.01.003

Kazaks, I., Na, L., Sophie, F., Alex, R., Vincenzo, C., Benjamin, B., et al. (2017). Production and purification of chimeric HBe virus-like particles carrying influenza virus LAH domain as vaccine candidates. *BMCMicrobiol.* 17:79. doi: 10.1186/s12896-017-0396-8

Klein, K. C., Polyak, S. J., and Lingappa, J. R. (2018). Rapid acquisition and model-based analysis of cell-free transcription–translation reactions from nonmodel bacteria. *Proc. Natl. Acad. Sci. U.S.A.* 115, E4340–E4349. doi: 10.1073/pnas.1715806115

Ludwig, C., and Wagner, R. (2007). Virus-like particles: a viable option for stratified medicines manufacturing? *Curr. Opin. Chem. Eng.* 18, 77–83. doi: 10.1016/j.coche.2017.10.003

Lee, M. F. X., Chan, E. S., Tan, W. S., Tam, K. C., and Tey, B. T. (2015). Purification of the recombinant hepatitis B core antigen, and its potential use for the diagnosis of hepatitis B virus infection. *Microb. Biotechnol.* 8, 53–61. doi: 10.1111/1751-7915.12173

Maity, B., Fujita, K., and Ueno, T. (2015). Use of the confined spaces of apo-ferritin in influenza virus LAH domain as vaccine candidates. *Virology* 468, 33–42. doi: 10.1016/j.virol.2015.08.056

Mehta, P. A., Rebala, K. C., Venkataraman, G., and Parida, A. (2009). A diurnally regulated dehydrin from Avicennia marina that shows nucleo-cytoplasmic localization and is phosphorylated by Casein kinase II in vitro. *Plant Physiol. Biochem.* 47, 701–709. doi: 10.1016/j.phyto.2009.03.008

Morin, S. J., Lai, H. E., Needham, H., Polizzi, K. M., and Freemont, P. S. (2017). Streptomyces venezuelae TX1-TL – a next generation cell-free synthetic biology tool. *Biotechnol. J.* 12:160668. doi: 10.1002/biot.201606678

Nardin, E. H., Oliveira, G. A., Calvo-Calle, J. M., Wetzel, K., Maier, C., Birkett, A. J., et al. (2004). Phase I testing of a malaria vaccine composed of hepatitis B Virus Core Particles Expressing Plasmodium falciparum circumsporozoite epitopes. *Infect. Immun.* 72, 6519–6527. doi: 10.1128/iai.72.11.6519-6527.2004

Ng, M. Y., Tan, W. S., Abdullah, N., Ling, T. C., and Tey, B. T. (2006). Heat treatment of unclarified *Escherichia coli* homogenate improved the recovery efficiency of recombinant hepatitis B core antigen. *J. Virol.* Methods 137, 134–139. doi: 10.1016/j.jvirometry.2006.06.016

Ogura, Y., Kato, K., Uchiyama, T., Sugiyama, H., Watanabe, K. I., Ikezawa, Z., et al. (2001). Rapid purification of Plasmodium falciparum circumsporozoite protein using cell-free protein synthesis system: a suitable system for high-level production of recombinant proteins. *J. Biotechnol.* 89, 299–310. doi: 10.1016/S0168-9452(01)00207-7

Pardee, K., Green, A. A., Takahashi, M. K., Braff, D., Lambert, G., Lee, J. W., et al. (2016). Rapid, Low-Cost Detection of Zika Virus Using Programmable Biomolecular Components. *Cell* 165, 1255–1266. doi: 10.1016/j.cell.2016.04.059

Pardee, K., Green, A. A., Takahashi, M. K., Braff, D., Lambert, G., Lee, J. W., et al. (2016). Rapid, Low-Cost Detection of Zika Virus Using Programmable Biomolecular Components. *Cell* 165, 1255–1266. doi: 10.1016/j.cell.2016.04.059

Patterson, D., Edwards, E., and Douglas, T. (2015). Hybrid nanoreactors: coupling enzymes and small-molecule catalysts within virus-like particles. *Israel J. Chem.* 55, 96–101. doi: 10.1002/ijch.201400092

Patterson, D. P., McCoy, K., Fijen, C., and Douglas, T. (2014). Constructing catalytic antimicrobial nanoparticles by encapsulation of hydrogen peroxide producing enzyme inside the P22 VLP. *J. Mater. Chem. B* 2:5948. doi: 10.1039/c4tb00983e

Pumpens, P., and Greens, E. (2001). HBV Core Particles as a Carrier for B Cell/T Cell Epitopes. *Intervirology* 44, 98–114. doi: 10.1159/000050037

Roldão, A., Mellado, M. C. M., and Crowther, R. A. (2012). Structures of hepatitis B virus cores presenting a model epitope and their complexes with antibodies. *J. Mol. Biol.* 423, 63–78. doi: 10.1016/j.jmb.2012.06.032

Rösselmann, M., Hughes, J., Phillips, T. R., and Milich, D. R. (2002). A malaria vaccine candidate based on a hepatitis B virus core platform. *Exp. Rev. Vaccines* 1, 39–52. doi: 10.1586/14730175.1.1.39

Schödel, F., Wirtz, R., Peterson, D., Hughes, J., Warren, R., and Sadowski, P. (1994). Immunity to malaria elicited by hybrid hepatitis B virus core particles carrying circumsporozoite protein epitopes. *J. Exp. Med.* 180, 1037–1046. doi: 10.1084/jem.180.3.1037

Sällberg, M., Hughes, J., Jones, J., Phillips, T. R., and Milich, D. R. (2002). A malaria vaccine candidate based on a hepatitis B virus core platform. *Intervirology* 45, 350–361. doi: 10.1159/000067928

Schödel, F., Wirtz, R., Peterson, D., Hughes, J., Warren, R., and Sadowski, J. (1994). Immunity to malaria elicited by hybrid hepatitis B virus core particles carrying circumsporozoite protein epitopes. *J. Exp. Med.* 180, 1037–1046. doi: 10.1084/jem.180.3.1037

Schwarz, B., and Douglas, T. (2015). Development of virus-like particles for diagnostic and prophylactic biomedical applications. *Wiley Interdiscip. Rev.* 7, 732–735. doi: 10.1002/wat2.1336

Sheng, J., Lei, S., Yuan, L., and Feng, X. (2017). Cell-free protein synthesis of norovirus virus-like particles. *RSC Adv.* 7, 28837–28840. doi: 10.1039/c7ra03742b

Spice et al. 2019
Spice et al. Cell-Free Production of VLPs

Smith, M. T., Varner, C. T., Bush, D. B., and Bundy, B. C. (2012). The incorporation of the A2 protein to produce novel Qβ virus-like particles using cell-free protein synthesis. Biotechnol. Prog. 28, 549–555. doi: 10.1002/btpr.744

Sogut, I., Hatipoglu, I., Kanbak, G., and Basalp, A. (2002). Purification of the recombinant hepatitis B core antigen, and its potential use for the diagnosis of hepatitis B virus infection. Biotechnol. Appli. 19, 138–142. doi: 10.1089/bi.yh.2011.0562

Stech, M., Quast, R. B., Sachse, R., Schulze, C., Wüsthenagen, D. A., and Kubick, S. (2014). A continuous-exchange cell-free protein synthesis system based on extracts from cultured insect cells. PloS One 9:e96635. doi: 10.1371/journal.pone.0096635

Storni, T., and Bachmann, M. F. (2004). Loading of MHC Class I and II Presentation Pathways by Exogenous Antigens: A Quantitative In Vivo Comparison. J. Immunol. 172, 6129–6135. doi: 10.4049/jimmunol.172.10.6129

Tan, Z., Maguire, M. L., Loeb, D. D., and Zlotnick, A. (2013). Genetically altering the thermodynamics and kinetics of hepatitis B virus capsid assembly has profound effects on virus replication in cell culture. J. Virol. 87, 3208–3216. doi: 10.1128/JVI.03014-12

Wang, M., Jiang, S., and Wang, Y. (2016). Recent advances in the production of recombinant subunit vaccines in Pichia pastoris. Bioengineered 7, 155–165. doi: 10.1080/21655979.2016.1191707

Wang, X., Liu, J., Zheng, Y., Li, J., Wang, H., and Zhou, Y. (2008). An optimized yeast cell-free system: Sufficient for translation of human papillomavirus 58 L1 mRNA and assembly of virus-like particles. J. Biosci. Bioeng. 106, 8–15. doi: 10.1263/jbb.106.8

Wetzel, D., Rolf, T., Suckow, M., Krantz, A., Barbin, A., and Chan, J. (2018). Establishment of a yeast-based VLP platform for antigen presentation. Microb. Fact. 17:17. doi: 10.1186/s12934-018-0868-0

Wingfield, P. T., Stahl, S. J., Williams, R. W., and Steven, A. C. (1995). Hepatitis core antigen produced in Escherichia coli: subunit composition, conformation analysis, and in vitro capsid assembly. Biochemistry 34, 4919–4932. doi: 10.1021/bi00015a003

Wnêk, M., Görzny, M. L., Ward, M. B., Wälti, C., Davies, A. G., and Brydon, R. (2013). Fabrication and characterization of gold nanowires templated on virus-like arrays of tobacco mosaic virus coat proteins. Nanotechnology 24:025605. doi: 10.1088/0957-4484/24/2/025605

Yang, H.-J. (2005). Expression and immunoactivity of chimeric particulate antigens of receptor binding site-core antigen of hepatitis B virus. World J. Gastroenterol. 11:492. doi: 10.3748/wjg.v11.i4.492

Zlotnick, A., Cheng, N., Conway, J. F., Booy, F. P., Steven, A. C., and Stahl, S. J. (1996). Dimorphism of Hepatitis B Virus Capsids Is Strongly Influenced by the C-Terminus of the Capsid Protein. Biochemistry 35, 7412–7421. doi: 10.1021/bi9604800

Zlotnick, A., Palmer, L., Kaufman, J. D., Stahl, S. J., Steven, A. C., and Wingfield, P. T. (1999). Separation and crystallization of T = 3 and T = 4 icosahedral complexes of the hepatitis B virus core protein. Acta Crystallogr. Section D Biol. Crystallogr. 55, 717–720. doi: 10.1107/s090744499801350x

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2020 Spice, Aw, Bracewell and Polizzi. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.